text: <unk>  <unk> , also known as chloroma) was first discovered by Allen Burns, a British physician, in 1811. The term chloroma was first used by King to address the greenish appearance of the tumor due to myeloperoxidase. The association of the<unk>  with acute myeloid leukemia (AML) was first recognized by Dock in 1902.<unk>  can be classified into two categories based on its co-occurence with other malignancies. Infiltration of the tumor with myeloblasts is the main characteristic of the tumor on H&E stain.<unk>  rises from primitive precursors of granulocytes. The disease is an extramedullary manifestation of myeloid diseases, however, it can occur as a primary disease. Aggregation of myeloblasts, promyelocytes and myelocytes outside of the bone marrow presents itself as these solid tumors. Tumors can occur at any site and can appear as green, gray, white or brown masses. <unk>  must be differentiated from other diseases that can present as extramedullary solid tumors. All patients with<unk>  must be evaluated for concurrent or future malignancies as<unk>  can occur in the course of or prior to other malignancies. The prevalence of<unk>  is approximately 2 per 1,000,000 individuals worldwide. The most important risk factor for development of<unk>  is genetic mutations and susceptibility.  Symptoms of<unk>  may include the following: Symptoms due to mass effect such as deafness, ptosis, altered vision, intestinal obstruction, headache, neck pain, abdominal pain, and constitutional symptoms. Chemotherapy is the main stain of treatment in patients with<unk> . Even patients with isolated<unk>  must receive systemic treatment to better the prognosis.
option_0: Granulocytic sarcoma
option_1: Reticulum cell sarcoma
option_2: Malignant histiocytosis
option_3: Epithelioid sarcoma
option_4: Alveolar soft part sarcoma
option_5: Malignant fibrous histiocytoma
option_6: Kaposiform hemangioendothelioma
option_7: Soft tissue sarcoma